Case Reports in Psychiatry
September 3, 2026
Sonali Notani, Vikas Srinivasa, Serena Chaudhry et al.
Hallucinogen persisting perception disorder (HPPD) is a rare psychiatric diagnosis encompassing a range of perceptual disturbances caused by the lingering effects of hallucinogens. There are two major subtypes of the disorder: HPPD I and II. HPPD II is considered a more severe form that is generally longer-term, distressing, and requiring more intense treatment. In the limited available...
medRxiv
July 19, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
preprint
Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...
July 10, 2026
Lohani Noor
A resurgent therapeutic frontier, the contemporary renaissance in psychedelic science has accelerated investigation of classic serotonergic psychedelics (psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline), empathogenic entactogenic agents (3,4-methylenedioxymethamphetamine (MDMA)), and glutamatergic dissociatives (ketamine) as adjuncts to psychotherapy. While...
Journal of Science Policy & Governance
July 2, 2026
Matthew A. Boehm, Oriana Mayorga
There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...
Journal of Psychopharmacology
June 25, 2026
Pavan S Brar, Rebecca B Price, Stephen Ross et al.
In the past decade, interest in studying psychedelic compounds as potential therapeutic agents has resurged. These studies carefully exclude individuals at risk for developing psychotic symptoms in response to psychedelic use. Given the potential for psychedelics to be established as treatments in psychiatry, it is important to more robustly understand their link with psychosis and...
Acta Neuropsychiatrica
June 10, 2026
Helerin Raikkerus, Andrea Bujour, Mark Kennedy et al.
Attention deficit and hyperactivity disorder (ADHD) is a prevalent neuropsychiatric disorder (Drechsler et al., 2020). Recently, psychedelics have become of interest regarding developing treatment options for ADHD. The aim of this systematic review is to find all studies from the APA PsychInfo and MEDLINE databases, where psychedelics have been used for ADHD and assess whether further clinical...
European Psychiatry
June 1, 2026
Michał Pastuszak, Katarzyna Jakuszkowiak‐wojten, Maria Gałuszko‐węgielnik et al.
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
Neuroscience & Biobehavioral Reviews
June 1, 2026
Javier Hidalgo Jiménez, Karl Kristjan Kaup, Jaan Aru
1 citation
Serotonergic psychedelics are known for their profound effects on consciousness and are gaining renewed interest as potential psychiatric treatments. These advances underscore the need to clarify the mechanisms of action of these compounds. This systematic review compiles and critically evaluates 23 in vitro and 26 in vivo electrophysiological studies on psychedelic compounds, with an emphasis...
UNC Libraries
May 21, 2026
Gavin P. Schmitz
Psychedelics are seeing renewed interest due to their potential as therapeutic tools; however, despite promising clinical findings, the underlying signaling mechanisms and brain-region specific effects of psychedelics remain unclear. This dissertation first describes a comprehensive study aimed at understanding the on and off-target actions of ~40 diverse psychedelic substances representing...
Journal of Psychopharmacology
May 1, 2026
Brian O'Mahony, Colm Harrington, Andrew Harkin et al.
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a "bad trip." Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require...